Neurogenic Detrusor Overactivity Clinical Trial
Official title:
An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.
This was a phase 3, open-label, baseline-controlled, multicenter study. The study consisted of 3 periods: Pretreatment period: for a maximum of 28 days before baseline, including screening, washout (if applicable) and baseline. Efficacy treatment period: beginning the day after baseline and continuing to week 24. Long-term safety period: beginning after week 24 and continuing to week 52 (end of study [EOS]), or to the end of treatment (EOT). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01981954 -
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
|
Phase 3 | |
| Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
| Terminated |
NCT00712322 -
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
|
Phase 2 | |
| Recruiting |
NCT06059066 -
Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
|
N/A | |
| Completed |
NCT01091727 -
Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity
|
Phase 3 | |
| Recruiting |
NCT05491525 -
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
|
Phase 2/Phase 3 | |
| Completed |
NCT02138149 -
Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury?
|
N/A | |
| Completed |
NCT04478357 -
BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG
|
Phase 1 | |
| Completed |
NCT00857896 -
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
|
Phase 2 | |
| Completed |
NCT00800462 -
Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity
|
Phase 4 | |
| Completed |
NCT01539707 -
Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder
|
Phase 1 | |
| Completed |
NCT03482037 -
Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury
|
Phase 1/Phase 2 | |
| Completed |
NCT04452838 -
Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer
|
Phase 1 | |
| Active, not recruiting |
NCT05502614 -
Dorsal Genital Nerve Stimulation for Bladder Management After SCI
|
N/A | |
| Recruiting |
NCT05621616 -
A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity
|
Phase 3 | |
| Withdrawn |
NCT01043848 -
Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Injury (SCI) Patients
|
N/A | |
| Completed |
NCT02526979 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
|
Phase 1 | |
| Completed |
NCT01565694 -
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
|
Phase 3 | |
| Completed |
NCT03168828 -
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
|
Phase 1 |